Delta3, FTHMA-070, Tango85, Tango77, SPOIL,NEOKINE, Tango129 and integrin alpha subunit protein and nucleic acid molecules and uses thereof

Abstract

The invention provides novel Delta3, FTHMA-070, Tango85, Tango77, SPOIL, NEOKINE, Tango129 and A259 polypeptides, proteins, and nucleic acid molecules. In addition to isolated, full-length Delta3, FTHMA-070, Tango85, Tango77, SPOIL, NEOKINE, Tango129 and A259 proteins, the invention further provides isolated Delta3, FTHMA-070, Tango85, Tango77, SPOIL, NEOKINE, Tango129 and A259 fusion proteins, antigenic peptides and anti-Delta3, FTHMA-070, Tango85, Tango77, SPOIL, NEOKINE, Tango129 and A259 antibodies. The invention also provides Delta3, FTHMA-070, Tango85, Tango77, SPOIL, NEOKINE, Tango129 and A259 nucleic acid molecules, recombinant expression vectors containing a nucleic acid molecule of the invention, host cells into which the expression vectors have been introduced and non-human transgenic animals in which a Delta3, FTHMA-070, Tango85, Tango77, SPOIL, NEOKINE, Tango129 or A259 gene has been introduced or disrupted. Diagnostic, screening and therapeutic methods utilizing compositions of the invention are also provided.

1 . An isolated nucleic acid molecule selected from the group consisting of: 
 (a) a nucleic acid molecule comprising a nucleotide sequence which is at least 90% identical to the nucleotide sequence of SEQ ID NO: 1, 3, 24, 26, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 53, 55, 57, 58, 71, 73, 76, 80, 89, 101, 104, 112, 115, 118, 121, 124, 137, 139, 145, 146, 163 or 164, or a complement thereof;    (b) a nucleic acid molecule comprising a fragment of at least 30 nucleotides of a nucleic acid comprising the nucleotide sequence of SEQ ID NO:1, 3, 24, 26, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 53, 55, 57, 58, 71, 73, 76, 80, 89, 101, 104, 112, 115, 118, 121, 124, 137, 139, 145, 146, 163 or 164, or a complement thereof;    (c) a nucleic acid molecule which encodes a polypeptide comprising an amino acid sequence at least about 90% identical to the amino acid sequence of SEQ ID NO:2, 25, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 54, 56, 58, 72, 77, 79, 81, 83, 90, 93, 102, 105, 116, 119, 122, 135, 138, 140, 147 or 165, or a complement thereof; and    (d) a nucleic acid molecule which encodes a fragment of a polypeptide comprising the amino acid sequence of SEQ ID NO: 2, 25, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 54, 56, 58, 72, 77, 79, 81, 83, 90, 93, 102, 105, 116, 119, 122, 135, 138, 140, 147 or 165, wherein the fragment comprises at least 10 contiguous amino acid residues of the amino acid sequence of SEQ ID NO: 2, 25, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 54, 56, 58, 72, 77, 79, 81, 83, 90, 93, 102, 105, 116, 119, 122, 135, 138, 140, 147 or 165, or a complement thereof.    
     
     
         2 . The isolated nucleic acid molecule of  claim 1 , wherein the isolated nucleic acid is selected from the group consisting of: 
 (a) a nucleic acid molecule comprising the nucleotide sequence set forth in SEQ ID NO:1, 3, 24, 26, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 53, 55, 57, 58, 71, 73, 76, 80, 89, 101, 104, 112, 115, 118, 121, 124, 137, 139, 145, 146, 163 or 164, or a complement thereof; and    (b) a nucleic acid molecule which encodes a polypeptide comprising the amino acid sequence set forth in SEQ ID NO:2, 25, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 54, 56, 58, 72, 77, 79, 81, 83, 90, 93, 102, 105, 116, 119, 122, 135, 138, 140, 147 or 165 or a complement thereof.    
     
     
         3 . An isolated nucleic acid molecule comprising the nucleic acid molecule of  claim 1  and a nucleotide sequence encoding a heterologous polypeptide.  
     
     
         4 . A vector comprising the nucleic acid molecule of  claim 1 .  
     
     
         5 . The vector of  claim 4 , which is an expression vector.  
     
     
         6 . A host cell transfected with the expression vector of  claim 5 .  
     
     
         7 . A method of producing a polypeptide comprising culturing the host cell of  claim 6  in an appropriate culture medium, to thereby produce the polypeptide.  
     
     
         8 . An isolated polypeptide selected from the group consisting of: 
 a) a polypeptide comprising the amino acid sequence of SEQ ID NO:2, 25, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 54, 56, 58, 72, 77, 79, 81, 83, 90, 93, 102, 105, 116, 119, 122, 135, 138, 140, 147 or 165;    b) a polypeptide consisting of the amino acid sequence of SEQ ID NO:2, 25, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 54, 56, 58, 72, 77, 79, 81, 83, 90, 93, 102, 105, 116, 119, 122, 135, 138, 140, 147 or 165;    c) a fragment of a polypeptide comprising the amino acid sequence of SEQ ID NO:2, 25, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 54, 56, 58, 72, 77, 79, 81, 83, 90, 93, 102, 105, 116, 119, 122, 135, 138, 140, 147 or 165, wherein the fragment comprises at least 10 contiguous amino acids of SEQ ID NO:2, 25, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 54, 56, 58, 72, 77, 79, 81, 83, 90, 93, 102, 105, 116, 119, 122, 135, 138, 140, 147 or 165;    d) a naturally occurring allelic variant of a polypeptide comprising the amino acid sequence of SEQ ID NO:2, 25, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 54, 56, 58, 72, 77, 79, 81, 83, 90, 93, 102, 105, 116, 119, 122, 135, 138, 140, 147 or 165, wherein the polypeptide is encoded by a nucleic acid molecule which hybridizes to complement of a nucleic acid molecule consisting of SEQ ID NO:1, 3, 24, 26, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 53, 55, 57, 58, 71, 73, 76, 80, 89, 101, 104, 112, 115, 118, 121, 124, 137,139, 145, 146, 163 or 164 under stringent conditions;    e) a polypeptide which is encoded by a nucleic acid molecule comprising a nucleotide sequence which is at least 90% identical to a nucleic acid comprising the nucleotide sequence of SEQ ID NO:1, 3, 24, 26, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 53, 55, 57, 58, 71, 73, 76, 80, 89, 101, 104, 112, 115, 118, 121, 124, 137, 139, 145, 146, 163 or 164; and    f) a polypeptide comprising an amino acid sequence which is at least 90% identical to the amino acid sequence of SEQ ID NO:2, 25, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 54, 56, 58, 72, 77, 79, 81, 83, 90, 93, 102, 105, 116, 119, 122, 135, 138, 140, 147 or 165.    
     
     
         9 . The polypeptide of  claim 8 , further comprising heterologous amino acid sequences.  
     
     
         10 . An antibody which selectively binds to a polypeptide of  claim 8 .  
     
     
         11 . A method for detecting the presence of a polypeptide of  claim 8  in a sample comprising: 
 a) contacting the sample with a compound which selectively binds to the polypeptide; and    b) determining whether the compound binds to the polypeptide in the sample to thereby detect the presence of a polypeptide of  claim 8  in the sample.    
     
     
         12 . The method of  claim 11 , wherein the compound which binds to the polypeptide is an antibody.  
     
     
         13 . A kit comprising a compound which selectively binds to a polypeptide of  claim 8  and instructions for use.  
     
     
         14 . A method for detecting the presence of a nucleic acid molecule of  claim 1  in a sample comprising: 
 a) contacting the sample with a nucleic acid probe or primer which selectively hybridizes to the nucleic acid molecule; and    b) determining whether the nucleic acid probe or primer binds to a nucleic acid molecule in the sample to thereby detect the presence of a nucleic acid molecule of  claim 1  in the sample.    
     
     
         15 . The method of  claim 14 , wherein the sample comprises mRNA molecules and is contacted with a nucleic acid probe.  
     
     
         16 . A kit comprising a compound which selectively hybridizes to a nucleic acid molecule of  claim 1  and instructions for use.  
     
     
         17 . A method for identifying a compound which binds to a polypeptide of  claim 8  comprising: 
 a) contacting the polypeptide, or a cell expressing the polypeptide with a test compound; and    b) determining whether the polypeptide binds to the test compound.    
     
     
         18 . The method of  claim 17 , wherein the binding of the test compound to the polypeptide is detected by a method selected from the group consisting of: 
 a) detection of binding by direct detection of test compound/polypeptide binding;    b) detection of binding using a competition binding assay; and    c) detection of binding using an assay for Delta3, FTIMA-070, Tango85, Tango77, SPOIL, NEOKINE, Tango129 or A259 activity.    
     
     
         19 . A method for modulating the activity of a polypeptide of  claim 8  comprising contacting the polypeptide or a cell expressing the polypeptide with a compound which binds to the polypeptide in a sufficient concentration to modulate the activity of the polypeptide.  
     
     
         20 . A method for identifying a compound which modulates the activity of a polypeptide of  claim 8  comprising: 
 a) contacting a polypeptide of  claim 8  with a test compound; and    b) determining the effect of the test compound on the activity of the polypeptide to thereby identify a compound which modulates the activity of the polypeptide.